833 Malignancies in Children Receiving Infliximab and Other Inflammatory Bowel Disease Therapies: An Inflammatory Bowel Disease Multicenter, Prospective, Long-Term Registry of Pediatric Patients (Develop) Registry Data
Richard B. Colletti(Greenville College), Gigi Veereman, Jeffrey S. Hyams(Connecticut Children's Medical Center), William A. Faubion(Mayo Clinic in Arizona), Johanna C. Escher(Erasmus MC - Sophia Children’s Hospital), Robert N. Baldassano(Children's Hospital of Philadelphia), James Markowitz, Frank Ruemmele(Hôpital Necker-Enfants Malades), Anja Geldhof, Salvatore Cucchiara(Massachusetts General Hospital), Sibylle Koletzko(LMU Klinikum), Anne M. Griffiths(University of Toronto), Marla Dubinsky(Cedars-Sinai Medical Center), Harland S. Winter(Massachusetts General Hospital), P. Callegari, Benjamin D. Gold(Emory University), Mark R. Molenda, Kezhen L. Tang(Janssen (United States)), Subra Kugathasan(Children's Healthcare of Atlanta), John Fell(Chelsea and Westminster Hospital), Richard Wright(Center for Applied Linguistics)
Cited by 7
Related Papers
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k